We report the development of a two-site irnmunoradiometric assay for PTH( 1-84) based on two site-specific monoclonal antibodies-3B3 (radiolabelled antibody) specific for PTH(1-34) and ESQl (on solid phase) specific for PTH(74-84). Antibody 3B3 is sensitive to the oxidation of the methionine residues in PTH( 1-34) therefore hydrogen peroxide (0.1 M) is added to the incubation mixture. Validation studies confirm quantitative recovery of both oxidized and reduced PTH( 1-84). The assay has a minimum detection limit of 0.5 pmol/L and a range of I ,5-250 pmol/L with an intra-assay CV of less than 10% (2.8-250pmol/L less than 5% CV). Studies on clinical samples indicate good discrimination between normal subjects (mean 2.2 1 ; range 1.0-5.0 pmol/L) and patients with primary hyperparathyroidism (mean 2 I .0; range 5.8-100pmol/L) who in turn are well separated from patients with hypercalcaemia of malignancy (14/18 < 0.5 pmol/L). 2 Brown RC, Aston JP, Weeks 1. Woodhead JS. Circulating intact parathyroid hormone measured by a two-site immunochemiluminometric assay. J Clin Enducrinol 1987; 65: 407-14 3 Frolich M, Walma ST, Padson C, PdpapOUkIS SE. lmmunoradiometric assay for intact human parathyroid hormone: characteristics. clinical application and comparison with 3 radioimmunoassay. Ann Clin Biochem 1990; 11: 64-72 1364-7 166 Logue et al. monophosphate in normal men. J Endocrinol 1989; 19 Logue FC, Fraser WD, Gallacher SJ, et al. T h e loss of circadian rhythm for intact parathyroid hormone and nephrogenous cyclic A M P in patients with primary hyperparathyroidism. CIin Endocrinol 121: R1-R3 1990; 32: 475-83
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The development of two-site immunometric assays for intact parathyroid hormone, PTH (1-84), has been an important advance in the laboratory assessment of patients with disorders of calcium metabolism. The improved sensitivity and specificity of these assays has allowed greater discrimination between patients with either primary hyperparathyroidism or h ypercalcaemia of malignancy.'-3 It is of note, however, that all two-site immunometric assays for PTH( 1-84) so far published have employed affinity purified polyclonal antisera to the N-terminal sequence of the molecule. This fact reflects the difficulty of producing high avidity monoclonal antibodies (Mab) to the N-terminus of PTH ; which in turn may be related to the susceptibility to oxidation of the two methionine residues in positions 8 and 18 of the pe~tide.~. ' We have previously reported the production of rat/mouse monoclonal antibody (Mab) 3B3, specific for PTH , which shows a 10-fold preference for [met]-0-PTH( 1-84) compared to PTH . 6 We now report the use of M a b 3B3 in combination with M a b ESQ-1, specific for PTH(74-84), in a novel two-site immunometric assay (IRMA) for PTH . The assay incor-Correspondence: Dr F C Logue. 160 porates an oxidation step during the assay incubation period in order to ensure that both endogenous and synthetic standard PTH( 1-84) are in the same state of oxidation. The assay has been validated in terms of both analytical and clinical performance. 
MATERIALS AND METHODS

Monoclonal antibodies
The rat/mouse monoclonal antibody to PTH (1-34) 3B3 was produced by immunization of DA rats with PTH(1-34) peptide and fusion of the rat spleen cells with the mouse myeloma line X63 Ag8.653.6 The mouse monoclonal antibody specific for PTH(74-84) ESQl was produced by Dr K James, Department of Surgery, University of Edinburgh, and supplied by Novo Nordisk Laboratories, Cambridge, UK. 
Radioiodination of 3B3
IgG was obtained from ascitic fluid by treatment with I-octanoic acid according to the method of Steinbuch and Audran.8 Aliquots (20pg) were iodinated with 0.5 mCi carrier-free radioiodine by the solid phase lactoperoxidase method of Karoncn e t d.' to a spccific activity of 15-20 p c i / 1%. 
Preparation of ESQI-Sepharose CL-4B solidphase
Monoclonal IgG was coupled to Scpharose CL-4B using the l.I'-carbonyldiimidazole method of Chapman and Ratcliffe.'" Using 12mg of Mab IgG for the estimated mean uptake of IgG to lOmL Sepharose CL-4B was 46% (range 32.1-60.8% n = 5). This is equivalent to a mean ratio of 15pg IgC/mg gel (range 14-18pg/mg).
Preparation of standards
Synthetic PTH(1-84) was diluted in equine serum immediately prior to each assay from a stock aliquot stored at -80°C to give concentrations of 0.98. 3.9, 15.7. 62.5 and 250 pmol/L. Radiolabelled 383 (1OOpL; 100 000cpm/tube) diluted in assay buffer was added and the assay incubated overnight at room temperature. Sepharose-ESQI solid phase (100 pL; 1 mg gel/tube) was added and incubated for 2 h at room temperature with shaking. The solid phase was separated by centrifugation and washing ( x 3) with 2 m L saline/Tween20 (0.2% v/v). Tubes were counted for 120s and data reduction carried out using the WHO immunoassay programme." 
RESULTS
Optimization of hydrogen peroxide concentration in the incubation mixture
Since Mab 3B3 has a 10-fold preference for the oxidized form of PTH( 1 -84), maximum assay sensitivity with this reagent will depend upon conversion of PTH(1-84) into the [met]-0 form prior to signal measurement. This was assessed by the addition of hydrogen peroxide to the assay incubation buffer as described below:
Endogenous circulating PTH Patient samples were assayed at a range of concentrations of hydrogen peroxide (04.25 M).
centrations of hydrogen peroxide (0-0.25 M). The assay responses obtained with samples from five patients with various disorders of calcium metabolism are shown in Fig. l(a) . The assay responses increased in all samples in proportion to baseline (zero hyrogen peroxide) and plateaued around a final concentration in thc incubation mixture of 0.1 M hydrogen peroxide.
Synthetic P T H ( 1 -8 4 )
Figure I(b) shows the responses obtained with synthetic PTH(1-84) standards (0, 10 and 250 pmol/L) also assayed at a range of hydrogen peroxide concentrations (0-0.25 M). In this case. as the peptides oxidized on storage, there was no significant difference in response from basal (zero hydrogen peroxide) at low concentrations but the responses appeared to decrease at 0.25 M hydrogen peroxide. Consequently, hydrogen peroxide was added routinely to the solution of radiolabelled 3B3 to give a final concentration in the assay mixture of 0.1 M.
Validation of assay performance Response curve and precision pr"fi1e
A typical PTH(1-84) response curve and associated precision profile, calculated from the precision of duplicate pairs is shown in Fig. 2 . The assay had a minimum detection limit of 0.5pmol/L estimated from the 22% CV on the precision profile.'2 The intra-assay CV was less than 10% between 1.5 and 250pmol/L (2.8-250pmol/L < 5% CV) giving the assay an acceptably wide working range.
Comparison of o.ridized/reduced P T H I 1-84) .stand(ird.s
Preparations o f oxidizcd and reduced PTH were produccd from the same stock aliquot of synthetic PTH( 1-84) by the method of Tashijian e t a/.' These preparations were then diluted according to the protocol for assay standards. Figure 3 shows the response curves obtained for the oxidized and rcduced standard preparations compared to the standard curve in routine use. The potency of both oxidized and reduced PTH( 1-84) was essentially equivalent across the range of the standard curve (0-250 pmol/L).
Recovery ?f P T H ( 1-84)
PTH ( with chronic renal failure were assayed before and after the addition of Synthetic PTH(1-84) (IOpmol/L). The results are shown in Table 1 .
The recovery experiments indicate that the assay gave quantitative recovery of PTH(1-84). H ( 1-84) : interferenre.from P T H f r a g m e n t s
Specificity jiir P T
The response curve was unaffected by the addition of up to a 200 molar excess of the Cterminal fragment PTH(S3-84). The N-terminal fragment PTH(1-34) caused a saturation of binding at high PTH( 1-84) concentrations at a IS-fold molar excess ( Fig. 4(a) ). Serum samples from a patient with primary hyperparathyroidism (PTH( 1-84) 80 pmol/L) and three patients with elevated PTH( 1-84) concentrations (SO, 80 & lOOpmol/L) and varying serum creatinine concentrations (690, 830 & 1300 pmol/L, respectively) secondary to chronic renal failure were analysed at a range of dilutions. The results were plotted against the theoretical PTH( 1-84) concentration and compared to the synthetic PTH( 1-84) standard curve ( Fig. 4(b) ). All samples diluted parallel to the synthctic PTH(I-84) rcsponse curve with no evidence of interference from PTH fragments. 
Reference range and clinical groups
Serum samples, collected between 1000 and 1400h and separated within 30min of venepuncture, were collected and assayed for PTH( 1-84), following storage at -50°C for a maximum of 7 days, from the following groups:
Normal subjects. Fifty-seven healthy laboratory staff with mean age 30.3 years (range 20-53). The PTH(1-84) concentrations in these groups are compared in Fig. 5 . No difference was detected between the PTH(1-84) concentrations of male and female subjects. The results from the patients with hyperparathyroidism were all above the reference interval estimated from the normal subjects. However, six of the patients with hyperparathyroidism had results in the range 5.8-7.0 pmol/L, close to the upper limit of the reference interval, indicating there may be some overlap between the PTH(1-84) concentrations in normal subjects and patients with primary hyperparathyroidism. The results in hyperparathyroid patients were, however, well separated from those in patients with hypercalcaemia associated with malignancy.
All
DISCUSSION
The immunoradiometric assay developed is the first described using two site-specific monoclonal antibodies. The assay compares favourably in terms of minimum detection limit and working range to published assays for intact PTH l-84).1-3 The novel feature of this assay is the deliberate oxidation reaction employed during the incubation step which ensures that all the PTH(1-84) in the specimen is in the preferred [met]-0 state.
The sensitivity of the Mab 3B3 to the oxidation state of PTH is a characteristic previously described for polyclonal antisera' and probably not unusual in antisera raised to N-terminal peptides. The fact that this has not commonly been noted in PTH assays is probably because assays employing polyclonal antisera, raised to multiple epitopes of PTH, would not be expected to show the same sensitivity to the oxidation state as a system employing a Mab raised to a single epitope. The oxidation of samples to allow quantitation of total oxidized peptide has been described in an assay for the measurement of methionine enkephalin.I3 The validation studies have shown that this PTH(1-84) assay system gives quantitative recovery of oxidized and reduced PTH( 1-84).
Studies on the effect of oxidation on the biological activity of PTH peptides in animals have indicated either total ina~tivation'~ or an alteration in the spectrum of biological activity." Data on the effects of PTH oxidation in humans is limited, but the results of this study would be consistent with the previous observation that circulating PTH( 1-84) is mainly in the reduced form.' However, the reagents of the assay system could be employed to investigate whether alterations in the state of oxidation of circulating PTH(I-84) occur and whether they may be of physiological significance.
The tolerance of a 200-fold molar excess of C-terminal fragments in the optimized assay will prevent interference from samples from patients with established renal failure where gross elevations of C-terminal fragments can occur. The level of interference from PTH(1-34) is unlikely to be a problem in clinical samples as recent evidence indicates that circulating concentrations of PTH( 1-34) are 10w.l~ The parallel dilution and quantitatve recovery of PTH( 1-84) from samples from patients with hyperparathyroidism or renal failure are further evidence to support these conclusions.
The main clinical application of PTH(1-84) assays is the differential diagnosis of hypercalcaemia. The PTH( 1-84) results from this assay allow good discrimation between normal of the reference range.
The PTH( 1-84) concentrations in patients with hypercalcaemia of malignancy were well separated from those with primary hyperparathyroidism with most patients with malignancy having undetectable PTH( 1-84) concentrations. Other published assays for P T H (1-84) have shown a higher proportion of detectability in such patients than we observed in our series. Whilst the relative state of oxidation of circulating PTH( 1-84) may influence this observation the most probable explanation lies in the selection of patients, for in treated patients a small decrease in serum calcium can produce a rise in PTH(1-84) cven though the patient remains hypercalcaemic." T h u s the finding of detectable PTH( 1-84) in these patients may reflect decreases in calcium due t o either fluctations in the course of the malignant condition or in response t o the initiation of treatment such as rehydration.
In addition t o allowing excellent discrimination between clinical groups our assay has the ablity to measure P T H ( 1-84) concentrations in all normal subjects and to follow changes within the reference range with confidence. This feature has allowed the assay t o be employed in studies demonstrating the circadian rhythm of PTH (1-84) secretion in normal subjects" and the loss of rhythm in hyperparathyroid patients."
